Background: Thrombotic complications of coronavirus disease 2019 (COVID-19) are a
worrisome aspect of the disease due to their high incidence in critically ill patients and their …

Background Patients hospitalized with severe acute respiratory syndrome coronavirus 2
infection are at risk for thrombotic complications necessitating use of therapeutic …

A systemic inflammatory response occurs during SARS-CoV2 infection and is associated
with hypercoagulability and thrombotic events. From March 2020 in our hospital different …

Introduction A hypercoagulable condition was described in patients with coronavirus
disease 2019 (COVID-19) and proposed as a possible pathogenic mechanism contributing …

Coronavirus disease 2019 (COVID-19) is a new viral disease complicating with acute
thrombophylic conditions, probably also via an inflammatory burden. Anticoagulants are …

Introduction: The predominant coagulation abnormalities in patients with coronavirus
disease 2019 (COVID-19) suggest a hypercoagulable state and are consistent with …

Coagulopathy represents one of the most important determinants of morbidity and mortality
in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or …

Background Critically ill COVID-19 patients have a clear pattern of inflammation and
hypercoagulable state. The main aim of the study was to evaluate the outcome of severe …

ABSTRACT BACKGROUND: Venous thromboembolism or extensive thrombosis is relatively
common in patients with severe COVID-19 infection and has been associated with …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is responsible of
variable clinical manifestations, ranging from no symptoms to severe pneumonia with acute …